These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 35405339)

  • 21. Advances in self-assembled nanotechnology in tumor therapy.
    Kuang Y; Li Z; Chen H; Wang X; Wen Y; Chen J
    Colloids Surf B Biointerfaces; 2024 May; 237():113838. PubMed ID: 38484445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Next-Generation Polymeric Nanomedicines for Oncology: Perspectives and Future Directions.
    Fletcher NL; Kempe K; Thurecht KJ
    Macromol Rapid Commun; 2020 Sep; 41(18):e2000319. PubMed ID: 32767396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination antitumor therapy with targeted dual-nanomedicines.
    Dai W; Wang X; Song G; Liu T; He B; Zhang H; Wang X; Zhang Q
    Adv Drug Deliv Rev; 2017 Jun; 115():23-45. PubMed ID: 28285944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current understandings and clinical translation of nanomedicines for breast cancer therapy.
    Jiang Y; Jiang Z; Wang M; Ma L
    Adv Drug Deliv Rev; 2022 Jan; 180():114034. PubMed ID: 34736986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Commercial utilities and future perspective of nanomedicines.
    Malviya R; Fuloria S; Verma S; Subramaniyan V; Sathasivam KV; Kumarasamy V; Hari Kumar D; Vellasamy S; Meenakshi DU; Yadav S; Sharma A; Fuloria NK
    PeerJ; 2021; 9():e12392. PubMed ID: 34820175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in targeted gene silencing and cancer therapy by nanoparticle-based delivery systems.
    Liu H; Zhu X; Wei Y; Song C; Wang Y
    Biomed Pharmacother; 2023 Jan; 157():114065. PubMed ID: 36481408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies.
    Li J; Wang Q; Han Y; Jiang L; Lu S; Wang B; Qian W; Zhu M; Huang H; Qian P
    J Hematol Oncol; 2023 Jun; 16(1):65. PubMed ID: 37353849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic Patent Review of Nanoparticles in Drug Delivery and Cancer Therapy in the Last Decade.
    Ali Hazis NU; Aneja N; Rajabalaya R; David SR
    Recent Adv Drug Deliv Formul; 2021; 15(1):59-74. PubMed ID: 34602031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
    Hock SC; Ying YM; Wah CL
    PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanomedicine in cancer therapy.
    Fan D; Cao Y; Cao M; Wang Y; Cao Y; Gong T
    Signal Transduct Target Ther; 2023 Aug; 8(1):293. PubMed ID: 37544972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemically Modified Natural Polymer-Based Theranostic Nanomedicines: Are They the Golden Gate toward a
    Jaymand M
    ACS Biomater Sci Eng; 2020 Jan; 6(1):134-166. PubMed ID: 33463213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer nanomedicine: progress, challenges and opportunities.
    Shi J; Kantoff PW; Wooster R; Farokhzad OC
    Nat Rev Cancer; 2017 Jan; 17(1):20-37. PubMed ID: 27834398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanomedicines accessible in the market for clinical interventions.
    Gadekar V; Borade Y; Kannaujia S; Rajpoot K; Anup N; Tambe V; Kalia K; Tekade RK
    J Control Release; 2021 Feb; 330():372-397. PubMed ID: 33370576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends in Nanotechnology for in vivo Cancer Diagnosis: Products and Patents.
    do Nascimento T; Tavares M; Monteiro MSSB; Santos-Oliveira R; Todeschini AR; de Souza VT; Ricci-Júnior E
    Curr Pharm Des; 2020; 26(18):2167-2181. PubMed ID: 32072890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surface-Engineered Cancer Nanomedicine: Rational Design and Recent Progress.
    Ahmad J; Ameeduzzafar ; Ahmad MZ; Akhter H
    Curr Pharm Des; 2020; 26(11):1181-1190. PubMed ID: 32056517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Critical considerations for targeting colorectal liver metastases with nanotechnology.
    Arshad U; Sutton PA; Ashford MB; Treacher KE; Liptrott NJ; Rannard SP; Goldring CE; Owen A
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Mar; 12(2):e1588. PubMed ID: 31566913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polyester nanomedicines targeting inflammatory signaling pathways for cancer therapy.
    Sachi Das S; Singh SK; Verma PRP; Gahtori R; Sibuh BZ; Kesari KK; Jha NK; Dhanasekaran S; Thakur VK; Wong LS; Djearamane S; Gupta PK
    Biomed Pharmacother; 2022 Oct; 154():113654. PubMed ID: 36067568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Navigating zinc-involved nanomedicine in oncotherapy.
    Yao J; Zhang A; Qiu Y; Li Z; Wu X; Li Z; Wu A; Yang F
    Nanoscale; 2023 Mar; 15(9):4261-4276. PubMed ID: 36756840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted nanomedicine in cisplatin-based cancer therapeutics.
    Han Y; Wen P; Li J; Kataoka K
    J Control Release; 2022 May; 345():709-720. PubMed ID: 35367476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.